Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hologic (holx) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN SNOW who wrote (434)	3/7/2000 8:00:00 PM
From: Ron	Read Replies (1) \| Respond to of 447

Wake up HOLXers..time to rock and roll. Do I smell another NERX rolling down the pike ??? :)

To: JOHN SNOW who wrote (434)	10/31/2001 11:16:59 AM
From: Ron	Respond to of 447

Rock and Roll: Hologic, Inc. (Nasdaq: HOLX chart, msgs), a leading provider of specialized medical imaging equipment for women's health and digital radiographic applications, today announced receipt of marketing clearance from the Food and Drug Administration (FDA) for its Lorad Affinity Mammography System. Lorad, a division of Hologic located in Danbury, Connecticut, is an industry leader in the production of innovative mammography and minimally invasive breast biopsy systems. The Lorad Affinity is a high performance screen-film mammography system specifically developed to fill a market need for a cost-effective product, with performance characteristics similar to high-end systems. The Affinity System will be marketed globally and will be available in configurations utilizing Lorad innovations to improve mammographic image quality, including its award winning High Transmission Cellular (HTC(TM)) Grid technology and exclusive Fully Automatic Self-adjusting Tilt (F.A.S.T.) compression paddle. According to Jack W. Cumming, CEO and President of Hologic, "Receiving FDA marketing clearance for the Affinity is one more step in our ongoing initiative to provide the highest quality breast imaging products to meet the needs of every facet of the market. The Affinity product line will help strengthen Hologic's overall leadership position in breast imaging by providing expanded product offerings for cost-sensitive segments of the international and domestic marketplace. Development of the Affinity, combined with our recent advances in digital mammography, our demonstrated expertise in premier screen-film mammography systems and our strength in stereotactic biopsy systems provides a strong foundation for technological superiority in every breast imaging product line." Commenting on the FDA action, Pete Kershaw, Vice President and General Manager of Lorad said, "We are pleased to receive confirmation of marketing clearance from the FDA for the Affinity Mammography System. We believe this system provides a highly effective solution for value-driven customers seeking a quality product to meet their mammography needs. The introduction of this versatile system to the mammography community provides effective, expanded choices for this market niche and advances Lorad's commitment to improving women's healthcare by producing high-quality products for the early detection of breast cancer." The Company expects full commercial production of the Affinity to begin in the first quarter of 2002.

To: JOHN SNOW who wrote (434)	11/6/2001 11:49:22 AM
From: Ron	Read Replies (1) \| Respond to of 447

HOLX wasting no time rolling out the Lorad System: BEDFORD, Mass., Nov. 6 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX - news), today announced completion of an agreement between its Lorad division and Ethicon Endo-Surgery for non-exclusive distribution rights in the United States to Ethicon's minimally invasive breast biopsy device, the Mammotome ST. Under the terms of the agreement, Hologic may offer the Mammotome ST for purchase with Lorad's MultiCare(TM) and StereoLoc® II stereotactic breast biopsy systems. Lorad is a leading provider of state-of-the-art mammography and breast biopsy systems. According to Jack W. Cumming, CEO and President of Hologic, ``We are pleased to enter into this agreement with Ethicon Endo-Surgery. The Mammotome ST is fully compatible with Lorad's breast biopsy systems, the MultiCare and StereoLoc II, which use advanced digital imaging to pinpoint the precise location of areas for biopsy, ensuring the accuracy and efficiency of the procedure. We believe the capability to offer highly accurate breast biopsies with both our upright and prone stereotactic breast biopsy systems can be significantly enhanced through the use of this device.'' The Mammotome ST is a reliable diagnostic alternative to open surgical biopsy and can obtain multiple tissue samples through a single, small incision in the skin, under local anesthesia. Open surgical biopsy removes a larger section of tissue through a 1 - 3 inch incision, often under general anesthesia. Commenting on the agreement, Pete Kershaw, Vice President & General Manager of Lorad said, ``In fulfilling Lorad's commitment to the improvement of women's health, we continuously seek adjunctive technologies to enhance our existing product offerings. Use of the Mammotome ST with our breast biopsy systems provides practitioners a safe, innovative alternative to open surgical biopsy. We believe the agreement with Ethicon Endo-Surgery will be mutually beneficial and we are pleased to have the opportunity to offer our customers this complementary technology.''